COVID-19
PBAC recommends new Comirnaty NIP price
Pfizer secures backing for revised pricing of its Covid-19 vaccine as part of transition to NIP The Pharmaceutical Benefits Advisory Committee (PBAC) has accepted a revised pricing for the National …
Government ends universal Covid-19 vaccine program
At-risk patients to retain access to funded Covid-19 shots through NIP as government calls time on NCVP Free Covid-19 vaccinations will continue to be available for at-risk groups through the …
GLP-1s supplant Covid antiviral growth: Wesfarmers
As pharmacies looked to replace revenue from Covid antivirals, a new contender moved behind counters, a major player says Weight loss drugs have become a top earner for Priceline Pharmacy …
Telehealth tied to lower antibiotic prescribing
Do doctors feel more pressure to prescribe antibiotics in face-to-face settings? Australian researchers investigated GPs who frequently used telehealth wrote fewer antibiotic scripts than their professional peers, an Australian study …
COVID variant prompts vaccine calls
Pharmacists are being reminded to talk to patients about free COVID jabs, as a new variant’s transmissibility sparks worry Health authorities are calling for vulnerable Australians to get vaccinated against …
The push for MedTech tariff exemptions
Listed sleep apnoea mask-maker Resmed says it’s reprieved from US President Trump’s tariffs for now and its CEO will push for all MedTech to be exempt in his other role …
Vaccine maker tumbles on Trump tariff threat
Pharmaceuticals were initially spared from sweeping US tariffs, but that’s set to change, striking panic in local markets US President Donald Trump said he would introduce “a major tariff on …
‘Wait-and-see’ on RFK Jr’s vaccine impact: MedAdvisor
Software business MedAdvisor Solutions indicated it’s not “currently” expecting to take a hit from the new US health secretary’s vaccine sentiment, but it’s “somewhat of a wait-and-see” exercise It comes …
Summing it up
Molnupiravir accounts for largest share of Covid-19 oral antiviral market, government expenditure: drug utilisation committee Molnupiravir (Lagevrio) is the most popular Covid-19 antiviral of choice, according to new data published …
‘Backorder’ for 90% of rural, remote hospital meds
The government’s response to the Covid-19 inquiry report highlighted hospital pharmacist concerns about supply chain disruption The Covid-19 Response Inquiry Report, released on Tuesday (29 October 2024) made nine recommendations …
Covid-19 response inquiry backs full scope moves
Pharmacy sector welcomes Covid-19 Response Inquiry Report’s call for action on full scope of practice The Covid-19 Response Inquiry Report is calling for nationally consistent reforms “to allow health professionals …
Covid: Has it really been so long?
It’s now been four years since the Covid-19 pandemic was declared. It has driven changes in pharmacy, as in so much of healthcare, and indeed society. Where are we currently …